Skip to main content
Aprogen, Inc logo

Aprogen, Inc — Investor Relations & Filings

Ticker · 007460 ISIN · KR7007460009 KO Manufacturing
Open in API
Filings indexed 737 across all filing types
Latest filing 2021-10-22 M&A Activity
Country KR South Korea
Listing KO 007460

About Aprogen, Inc

https://www.aprogen.com/en/v.do?a=Main

Aprogen, Inc. is a biopharmaceutical company focused on the research, development, and manufacturing of biologic medicines. The company's core activities are centered on developing both biosimilars and novel drugs, including new protein therapeutics and bispecific antibodies. Its product development is based on proprietary technologies in antibody engineering and recombinant protein engineering.

Recent filings

Filing Released Lang Actions
[기재정정]주요사항보고서(회사합병결정)
M&A Activity Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) regarding a company merger (회사합병 결정) between Aprogen Medicines and Aprogen. It includes detailed information on the merger ratio, financial impact, external audit opinions, and shareholder rights (stock purchase rights). This type of filing is a formal regulatory disclosure regarding M&A activity. Since it is a comprehensive report detailing the merger terms rather than just an announcement of a report's publication, it is classified as M&A Activity.
2021-10-22 Korean
전환가액ㆍ신주인수권행사가액ㆍ교환가액의조정(안내공시)
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory announcement regarding the adjustment of the conversion price for convertible bonds (CB) due to a decline in the company's stock price. This type of filing, which details changes to the capital structure and potential future share issuance, falls under the category of 'Capital/Financing Update' (CAP) as it relates to the terms of existing financing instruments.
2021-10-21 Korean
투자판단관련주요경영사항(특허취득)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system, specifically titled 'Investment Judgment Related Major Management Matters' (투자판단 관련 주요경영사항). It details the acquisition of a patent for an antibody used in breast cancer treatment. Since this is a specific regulatory disclosure regarding a material corporate event (patent acquisition) that does not fit into categories like financial reports, dividends, or management changes, it falls under the general regulatory filing category.
2021-10-18 Korean
[첨부추가]증권신고서(합병)
M&A Activity Classification · 95% confidence The document is a 'Securities Registration Statement' (증권신고서) for a merger (합병) between Aprogen Medicines and Aprogen. It contains detailed information regarding the merger, investment risks, business descriptions, and financial data, which is characteristic of a formal regulatory filing for a corporate merger. In the context of financial filings, this is a primary document for a merger transaction, which falls under the 'M&A Activity' category.
2021-09-30 Korean
매매거래정지및정지해제(중요내용공시)
Delisting Announcement Classification · 100% confidence The document is a short regulatory notice regarding the suspension and resumption of trading for APROGEN MED due to a material disclosure (merger decision). It is a standard regulatory announcement issued to the market, which fits the 'Regulatory Filings' category as it does not fall into specific categories like M&A (which would be the merger document itself) or other financial reports.
2021-09-16 Korean
주요사항보고서(회사합병결정)
M&A Activity Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) regarding a merger decision (회사합병 결정) between Aprogen Medicines and Aprogen. It contains detailed information about the merger ratio, financial impact, external evaluation opinions, and shareholder rights (stock purchase rights). This type of filing is a formal regulatory disclosure regarding M&A activity, which falls under the 'M&A Activity' category.
2021-09-16 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.